CONMED (CNMD) Competitors

Penumbra (NYSE:PEN) and CONMED (NYSE:CNMD) are both mid-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, valuation, dividends, community ranking, earnings, risk and media sentiment.

Which has more risk and volatility, PEN or CNMD?

Penumbra has a beta of 0.51, suggesting that its stock price is 49% less volatile than the S&P 500. Comparatively, CONMED has a beta of 1.45, suggesting that its stock price is 45% more volatile than the S&P 500.

Which has preferable valuation & earnings, PEN or CNMD?

Penumbra has higher earnings, but lower revenue than CONMED. CONMED is trading at a lower price-to-earnings ratio than Penumbra, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Penumbra	$1.06B	8.62	$90.95M	$0.86	276.56
CONMED	$1.24B	1.79	$64.46M	$4.21	17.16

Do insiders and institutionals have more ownership in PEN or CNMD?

88.9% of Penumbra shares are owned by institutional investors. 5.0% of Penumbra shares are owned by insiders. Comparatively, 6.8% of CONMED shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Is PEN or CNMD more profitable?

CONMED has a net margin of 10.23% compared to Penumbra's net margin of 2.97%. CONMED's return on equity of 13.84% beat Penumbra's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Penumbra	2.97%	8.99%	6.80%
CONMED	10.23%	13.84%	5.26%

Do analysts prefer PEN or CNMD?

Penumbra currently has a consensus target price of $226.67, suggesting a potential downside of 4.70%. CONMED has a consensus target price of $79.80, suggesting a potential upside of 10.47%. Given CONMED's stronger consensus rating and higher probable upside, analysts clearly believe CONMED is more favorable than Penumbra.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Penumbra	0 Sell rating(s)	5 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.71
CONMED	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.80

Does the media prefer PEN or CNMD?

In the previous week, Penumbra had 3 more articles in the media than CONMED. MarketBeat recorded 6 mentions for Penumbra and 3 mentions for CONMED. CONMED's average media sentiment score of 1.37 beat Penumbra's score of 0.35 indicating that CONMED is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Penumbra	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
CONMED	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Does the MarketBeat Community favor PEN or CNMD?

Penumbra received 779 more outperform votes than CONMED when rated by MarketBeat users. Likewise, 80.26% of users gave Penumbra an outperform vote while only 47.22% of users gave CONMED an outperform vote.

Company	Underperform	Outperform
Penumbra	Outperform Votes 813 80.26%	Underperform Votes 200 19.74%
CONMED	Outperform Votes 34 47.22%	Underperform Votes 38 52.78%

Summary

Penumbra beats CONMED on 10 of the 19 factors compared between the two stocks.